Stocklytics Platform
Asset logo for symbol TFFP
TFF Pharmaceuticals
TFFP74
$1.87arrow_drop_up5.93%$0.10
High Growth
Penny Stock
Asset logo for symbol TFFP
TFFP74

$1.87

arrow_drop_up5.93%

Performance History

Chart placeholder
Key Stats
Open$1.74
Prev. Close$1.74
EPS-9.38
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$5.60M
PE Ratio-
LOWHIGH
Day Range1.70
1.86
52 Week Range1.54
13.50
Ratios
Revenue-
EBITDA Margin %-
EPS-9.38

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•
•

Correlated Companies

Asset logo for symbol LLY
Eli Lilly & Co
LLY74
Price$804.62
Perf. (24h)
arrow_drop_down2.01%-$16.57
Market Cap$724.48B
Asset logo for symbol UNH
UnitedHealth Group
UNH71
Price$569.71
Perf. (24h)
arrow_drop_up1.79%$10.03
Market Cap$527.83B
Asset logo for symbol JNJ
Johnson & Johnson
JNJ62
Price$160.64
Perf. (24h)
arrow_drop_up0.62%$1.00
Market Cap$386.60B
Asset logo for symbol ABBV
AbbVie
ABBV62
Price$185.16
Perf. (24h)
arrow_drop_up1.64%$2.99
Market Cap$326.96B

About TFF Pharmaceuticals (TFFP)

TFF Pharmaceuticals Inc (TFFP) is a pharmaceutical company that focuses on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform. The company's TFF technology enables the formulation and delivery of drugs in a convenient and efficient manner, improving patient compliance and treatment outcomes. With a vision to revolutionize the treatment of respiratory diseases, TFF Pharmaceuticals is committed to developing advanced therapies for various respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis.
As of the latest market data, TFF Pharmaceuticals Inc has a market capitalization of $XXX million, demonstrating its potential in the pharmaceutical industry. The company's stock, ticker symbol TFFP, has experienced notable volatility in the past year, with a 52-week range of $X.XX to $X.XX. The day range of TFFP indicates the stock's performance for the current trading session, providing insights into its intraday fluctuations.
Websitecall_made
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Harlan F. Weisman
Headquarters
Fort Worth
Employees
15
Exchange
NASDAQ
add TFF Pharmaceuticals to watchlist

Keep an eye on TFF Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is TFF Pharmaceuticals 's (TFFP) price per share?
The current price per share for TFF Pharmaceuticals (TFFP) is $1.88. The stock has seen a price change of $0.1 recently, indicating a 5.93% change. This reflects the stock's recent market performance and investor sentiment.
help
What is the 52-week high and low for TFF Pharmaceuticals (TFFP)?
For TFF Pharmaceuticals (TFFP), the 52-week high is $13.5, which is 620% from the current price. The 52-week low is $1.54, the current price is 21.75% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help
Is TFF Pharmaceuticals (TFFP) a growth stock?
TFF Pharmaceuticals (TFFP) has shown an average price growth of 0.41% over the past three years. It has received a score of 95 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying TFF Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help
What is TFF Pharmaceuticals (TFFP) stock price performance year to date (YTD)?
As of the latest data, TFF Pharmaceuticals (TFFP) has a year-to-date price change of -72.87%. Over the past month, the stock has experienced a price change of 8.38%. Over the last three months, the change has been -35.82%. Over the past six months, the figure is -62.74%.
help
Is TFF Pharmaceuticals (TFFP) a profitable company?
TFF Pharmaceuticals (TFFP) has a net income of -$21.24M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 31.53% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -2.85K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. The gross profit is $231.39K. Operating income is noted at -$22.63M. Furthermore, the EBITDA is -$20.08M.
help
What is the market capitalization of TFF Pharmaceuticals (TFFP)?
TFF Pharmaceuticals (TFFP) has a market capitalization of $5.67M. The average daily trading volume is 13.9K, indicating the stock's liquidity and investor engagement.

News

TFF Pharmaceuticals, Inc. (TFFP) Reports Q1 Loss, Tops Revenue Estimates
5/14/2024

TFF Pharmaceuticals, Inc. (TFFP) Reports Q1 Loss, Tops Revenue Estimates

TFF Pharmaceuticals Announces Closing of Pricing of $4.8 Million Public Offering
FINANCING AGREEMENTS
5/1/2024

TFF Pharmaceuticals Announces Closing of Pricing of $4.8 Million Public Offering

TFF Pharmaceuticals Announces Pricing of $4.8 Million Public Offering
INITIAL PUBLIC OFFERINGS
4/30/2024

TFF Pharmaceuticals Announces Pricing of $4.8 Million Public Offering

TFF Pharmaceuticals Makes Available Phase 2 Data from Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection Presented at the Recent ISHLT Annual Meeting
HEALTH
CLINICAL STUDY
4/29/2024

TFF Pharmaceuticals Makes Available Phase 2 Data from Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection Presented at the Recent ISHLT Annual Meeting

TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
EARNINGS RELEASES AND OPERATING RESULTS
3/28/2024

TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results

TFF Pharmaceuticals Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical Programs
CLINICAL STUDY
3/27/2024

TFF Pharmaceuticals Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical Programs

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level